Clinical trial
Alberta Cancer Exercise Dose in Colorectal Cancer
NCT07913906 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Interventional study, Phase 2, 90 participants (estimated). Lead sponsor University of Calgary; Canada. Primary measure: Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10...
How it compares
1,318 similar trials: same condition (Colorectal Neoplasms) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Alberta Cancer Exercise Dose in Colorectal Cancer
- Lead sponsor
- University of Calgary
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- January 31, 2029
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Colorectal Neoplasms, Neoplasms
Registry terms: cancer, colorectal cancer
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- Canada
- Lead sponsor
- University of Calgary
Arms
As registered; 3 arms.
| Arm | Type | Interventions |
|---|---|---|
| Once/week exercise session for 12 weeks (Arm 1) | Experimental | Group Exercise Classes - Arm 1 |
Show registry wordingArm 1 will be supervised by a CEP once a week (e.g. Tuesday or Thursday) at the ACCCC. The exercise program includes aerobic, strength and balance / flexibility exercises for 12 week. | ||
| Twice/week exercise session for 12 weeks (Arm 2) | Active comparator | Group Exercise Classes - Arm 2 |
Show registry wordingArm 2 will be supervised by a CEP twice a week (e.g. Tuesday and Thursday) at the ACCCC. The exercise program includes aerobic, strength and balance / flexibility exercises for 12 week. | ||
| Control-waitlisted group (Arm 3) | No intervention | |
Show registry wordingStandard of care control-waitlisted group to start the Thrive program after 24 weeks on a voluntary basis | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10 MET-h/wk of total physical activity level at 12 weeks. | Single time point: 12 weeks |
Show registry wordingTo assess the dose-response effect of exercise frequency (once versus twice weekly) over a 12-week period on clinically meaningful improvements in physical activity level (≥10 MET-h/wk increase over baseline) in patients with early-stage CRC receiving systemic treatment, with the goal of identifying the minimal effective intervention frequency | |
Lead sponsor's other trials
University of Calgary, most recent start first.
+697 more trials See the organization page
Similar trials
Same condition (Colorectal Neoplasms) and phase, most recent start first.
+1,313 more trials See the condition page